

State of Oklahoma SoonerCare





Jemperli® (dostarlimab-gxly) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Inform	ation
☐Physician billing (HCPCS code	CPCS code:)	
Dose: Regim	en:	_ Start Date (or date of next dose):
	Billing Provider Ir	nformation
Provider NPI:	Provider N	lame:
Provider Phone:	Provide	er Fax:
	Prescriber Info	rmation
Prescriber NPI:	Prescriber Nar	ne:
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
ii. Is disease misma iii. Has disease progressed C. Are there satisfactory tre iii. Is disease misma Yes \sum No \sum Wismatch Repair (dMMR) A. Is disease progressed C. Are there satisfactory tre	starlimab-gxly will be used: aced, recurrent, or metasta atch repair deficient (dMMF gressed on or following pri- carboplatin and paclitaxel ry advanced or recurrent e atch repair deficient (dMMF Solid Tumor advanced? Yes No d on or following prior treative eatment alternatives for the bove, please indicate dia	tic endometrial cancer? Yes No No R)? Yes No No No No reatment with a platinum-containing regimen? Indometrial cancer? Yes No No R) or microsatellite instability-high (MSI-H) disease? Indement? Yes No

(Page 1 of 2)

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 203 8/25/2023



State of Oklahoma SoonerCare



Jemperli® (dostarlimab-gxly) Prior Authorization Form

Member Name:	Date of Birth:		
	Criteria		
	 e of progressive disease whi	le on dostarlimab-gxly therapy? Yes	□ No □
 Has the member experienced a Yes No 	any adverse drug reactions re	elated to dostarlimab-gxly therapy?	
If yes, please specify adverse read	etions:		
Additional Information:	KA		
	(Page 2 of 2		
Prescriber Signature		Date:	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

knowledge. Failure to complete this form in full will result in processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 203 8/25/2023

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my